Buse, Dawn C. http://orcid.org/0000-0002-1223-1215
Reed, Michael L.
Fanning, Kristina M.
Bostic, Ryan
Dodick, David W.
Schwedt, Todd J.
Munjal, Sagar
Singh, Preeti
Lipton, Richard B.
Funding for this research was provided by:
Dr. Reedy's Laboratories (na)
Article History
Received: 12 October 2019
Accepted: 4 February 2020
First Online: 2 March 2020
Ethics approval and consent to participate
: The MAST Survey and respondent consent forms were reviewed by the Ethical and Independent Review Services (Independence, MO, USA) which granted an exemption from the federal regulation 45 CFR 46.101(b)(2). All survey respondents provided informed consent.
: Not applicable.
: SM and PS are employed by Dr. Reddy’s Laboratories; RBL, DCB, MLR, TJS, and DWD were paid consultants of Dr. Reddy’s Laboratories.DCB has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Novartis and Promius/Dr. Reddys. She has not been paid by any company for work writing manuscripts, or writing or presenting abstracts, posters or platforms. She serves on the editorial boards of Current Pain and Headache Reports, the Journal of Headache and Pain, Pain Medicine News, and Pain Pathways magazine.DWD: Consulting: Amgen, University Health Network, Daniel Edelman Inc., Autonomic technologies, Axsome, Allergan, Alder, Biohaven, Charleston Laboratories, Promius, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Theranica, Teva, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, Amzak Health. Honoraria: Foresite Capital, ZP Opco, Oppenheimer, Association of Translational Medicine, Healthlogix, Medicom Worldwide, Medlogix Communications, Mednet, Electrocore, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Sun Pharma (India), Universal meeting management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, Wolters Kluwer Health. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, and Patient Centered Outcomes Research Institute (PCORI). Stock Options/Shareholder/Patents/Board of Directors: Aural analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien (Options/Board), Nocira, Matterhorn/Ontologics (Options/Board), King-Devick Technologies (Options/Board), Precon Health (Options/Board). Patent 17189376.1–1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis.MLR, KMF, and RB are employees of Vedanta Research, which has received support funded by Allergan, Amgen, Colucid, Eli Lilly, NuPathe, Novartis, Ortho-McNeil and the National Headache Foundation.TJS received research support from the American Migraine Foundation, Henry Jackson Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, US Department of Defense, and Amgen. Within the past 12 months, he has served as a consultant or advisory board member for Alder, Allergan, Amgen, Avanir, Biohaven, Dr. Reddy’s, Eli Lilly, Equinox, Ipsen Bioscience, Novartis, Teva, and XoC Pharmaceuticals. He holds stock options in Aural Analytics, Nocira, and Second Opinion. He serves as an Associate Editor for Headache and Cephalalgia.RBL has received grant support from the National Institutes of Health, the National Headache Foundation, and the Migraine Research Fund. He serves as consultant, serves as an advisory board member, or has received honoraria from Alder, Allergan, American Headache Society, Autonomic Technologies, Biohaven, Eli Lilly, eNeura Therapeutics, Merck, Novartis, Pfizer, and Teva, Inc. He receives royalties from Wolff’s Headache, 8th Edition (Oxford University Press, 2009). He holds stock options in eNeura Therapeutics and Biohaven.